STOCK TITAN

[8-K] bioAffinity Technologies, Inc. Warrant Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Rezolve AI plc (RZLV) completed a $50 million private investment in public equity (PIPE) on 25 July 2025, issuing 20 million ordinary shares at $2.50 each under Reg D and §4(a)(2) exemptions.

A.G.P./Alliance Global Partners acted as placement agent, entitled to a 7.0 % cash fee (partly offset by a 3.5 % credit tied to specific purchasers) and up to $130 k in reimbursable expenses. Net proceeds will fund working capital, potential accretive M&A and general corporate needs.

Investors received robust registration rights: Rezolve must file a resale registration statement within 7 days of closing and achieve effectiveness within 30 days (60 days if fully reviewed). The company is barred from announcing or issuing additional equity for 60 days post-effectiveness, with limited carve-outs. Key agreements—including the Purchase Agreement, Placement Agent Agreement and Registration Rights Agreement—are filed as Exhibits 10.1-10.3.

Rezolve AI plc (RZLV) ha completato il 25 luglio 2025 un investimento privato in azioni pubbliche (PIPE) da 50 milioni di dollari, emettendo 20 milioni di azioni ordinarie a 2,50 dollari ciascuna, usufruendo delle esenzioni Reg D e §4(a)(2).

A.G.P./Alliance Global Partners ha agito come agente di collocamento, ricevendo una commissione in contanti del 7,0 % (parzialmente compensata da un credito del 3,5 % legato a specifici acquirenti) e fino a 130.000 dollari di spese rimborsabili. I proventi netti saranno utilizzati per il capitale circolante, potenziali acquisizioni che aumentano il valore e necessità aziendali generali.

Gli investitori hanno ottenuto solidi diritti di registrazione: Rezolve deve presentare una dichiarazione di registrazione per la rivendita entro 7 giorni dalla chiusura e ottenere l’efficacia entro 30 giorni (60 giorni se sottoposta a revisione completa). L’azienda è vincolata a non annunciare o emettere ulteriori azioni per 60 giorni dopo l’efficacia, con alcune limitate eccezioni. Gli accordi chiave — incluso il Contratto di Acquisto, l’Accordo con l’Agente di Collocamento e l’Accordo sui Diritti di Registrazione — sono depositati come Allegati 10.1-10.3.

Rezolve AI plc (RZLV) completó el 25 de julio de 2025 una inversión privada en acciones públicas (PIPE) por 50 millones de dólares, emitiendo 20 millones de acciones ordinarias a 2,50 dólares cada una bajo las exenciones Reg D y §4(a)(2).

A.G.P./Alliance Global Partners actuó como agente colocador, con derecho a una comisión en efectivo del 7,0 % (parcialmente compensada por un crédito del 3,5 % vinculado a compradores específicos) y hasta 130.000 dólares en gastos reembolsables. Los ingresos netos financiarán capital de trabajo, posibles fusiones y adquisiciones que aporten valor y necesidades corporativas generales.

Los inversores recibieron sólidos derechos de registro: Rezolve debe presentar una declaración de registro para reventa dentro de los 7 días posteriores al cierre y lograr la efectividad dentro de 30 días (60 días si se revisa completamente). La compañía tiene prohibido anunciar o emitir acciones adicionales durante 60 días después de la efectividad, con algunas excepciones limitadas. Los acuerdos clave —incluyendo el Acuerdo de Compra, el Acuerdo con el Agente Colocador y el Acuerdo de Derechos de Registro— están archivados como Anexos 10.1-10.3.

Rezolve AI plc (RZLV)는 2025년 7월 25일 5,000만 달러 규모의 사모 공개 주식 투자(PIPE)를 완료했으며, Reg D 및 §4(a)(2) 면제를 적용하여 주당 2.50달러에 2,000만 보통주를 발행했습니다.

A.G.P./Alliance Global Partners가 배치 에이전트로 활동했으며, 특정 구매자와 연계된 3.5% 크레딧 일부 상쇄를 포함해 7.0% 현금 수수료와 최대 13만 달러의 환급 가능한 비용을 받습니다. 순수익은 운전자본, 잠재적인 가치 증대 인수합병 및 일반 기업 필요에 사용될 예정입니다.

투자자들은 강력한 등록 권리를 받았습니다: Rezolve는 마감 후 7일 이내에 재판매 등록 신청서를 제출해야 하며, 30일 이내(완전 검토 시 60일 이내)에 효력을 얻어야 합니다. 회사는 효력 발생 후 60일 동안 제한된 예외를 제외하고 추가 주식 발행이나 공시를 할 수 없습니다. 주요 계약서—구매 계약서, 배치 에이전트 계약서 및 등록 권리 계약서—는 부속서 10.1-10.3으로 제출되었습니다.

Rezolve AI plc (RZLV) a finalisé le 25 juillet 2025 un investissement privé en actions cotées (PIPE) de 50 millions de dollars, émettant 20 millions d’actions ordinaires à 2,50 dollars chacune, bénéficiant des exemptions Reg D et §4(a)(2).

A.G.P./Alliance Global Partners a agi en tant qu’agent de placement, percevant une commission en espèces de 7,0 % (partiellement compensée par un crédit de 3,5 % lié à des acheteurs spécifiques) ainsi que jusqu’à 130 000 dollars de frais remboursables. Les produits nets financeront le fonds de roulement, d’éventuelles acquisitions créatrices de valeur et les besoins généraux de l’entreprise.

Les investisseurs ont obtenu des droits d’enregistrement solides : Rezolve doit déposer une déclaration d’enregistrement pour la revente dans les 7 jours suivant la clôture et obtenir son efficacité dans les 30 jours (60 jours en cas d’examen complet). La société est interdite d’annoncer ou d’émettre des actions supplémentaires pendant 60 jours après l’efficacité, avec quelques exceptions limitées. Les accords clés — y compris le contrat d’achat, le contrat d’agent de placement et le contrat de droits d’enregistrement — sont déposés en annexes 10.1 à 10.3.

Rezolve AI plc (RZLV) hat am 25. Juli 2025 eine private Investition in börsennotierte Aktien (PIPE) in Höhe von 50 Millionen US-Dollar abgeschlossen und dabei 20 Millionen Stammaktien zu je 2,50 US-Dollar unter den Ausnahmen gemäß Reg D und §4(a)(2) ausgegeben.

A.G.P./Alliance Global Partners fungierte als Platzierungsagent und erhielt eine Barprovision von 7,0 % (teilweise durch einen 3,5 % Kredit für bestimmte Käufer ausgeglichen) sowie bis zu 130.000 US-Dollar erstattungsfähige Auslagen. Die Nettoerlöse dienen der Finanzierung des Betriebskapitals, potenzieller wertsteigernder Fusionen und Übernahmen sowie allgemeinen Unternehmensbedarfen.

Die Investoren erhielten umfassende Registrierungsrechte: Rezolve muss innerhalb von 7 Tagen nach Abschluss eine Registrierungsanmeldung für den Weiterverkauf einreichen und innerhalb von 30 Tagen (60 Tage bei vollständiger Prüfung) die Wirksamkeit erreichen. Das Unternehmen darf für 60 Tage nach Wirksamkeit keine weiteren Aktien ankündigen oder ausgeben, mit begrenzten Ausnahmen. Die wichtigsten Vereinbarungen – einschließlich des Kaufvertrags, des Platzierungsagentenvertrags und des Registrierungsrechtsvertrags – sind als Anlagen 10.1-10.3 eingereicht.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: $50 m PIPE improves liquidity but dilutes shareholders; terms appear standard, near-term cash runway strengthened.

Analysis: The capital raise adds ≈$50 m gross, materially boosting cash for operations and M&A. At $2.50 per share, valuation impact hinges on the pre-transaction share count and market price (not disclosed here), but 20 m new shares will dilute existing holders. Registration rights with tight deadlines signal commitment to investor liquidity. A 7 % placement fee is typical; the 3.5 % credit partially mitigates cost. Sixty-day issuance lock-up limits further dilution risk in the short term. Overall, liquidity gains offset dilution, yielding a balanced impact.

TL;DR: Standard Reg D structure; strong registration covenants, customary indemnities, moderate lock-up enhance compliance profile.

Analysis: The PIPE relies on well-trodden §4(a)(2)/Rule 506(b) exemptions, minimizing registration delay. The company’s agreement to file within 7 days and achieve effectiveness within 30-60 days exceeds market-average timelines, reducing resale friction. Lock-up provisions protect investors from immediate dilution. Indemnities, expense caps and termination clauses mirror industry norms. No unusual contingencies or warrant structures appear, lowering legal complexity. Compliance risk is low; execution risk centers on timely SEC effectiveness.

Rezolve AI plc (RZLV) ha completato il 25 luglio 2025 un investimento privato in azioni pubbliche (PIPE) da 50 milioni di dollari, emettendo 20 milioni di azioni ordinarie a 2,50 dollari ciascuna, usufruendo delle esenzioni Reg D e §4(a)(2).

A.G.P./Alliance Global Partners ha agito come agente di collocamento, ricevendo una commissione in contanti del 7,0 % (parzialmente compensata da un credito del 3,5 % legato a specifici acquirenti) e fino a 130.000 dollari di spese rimborsabili. I proventi netti saranno utilizzati per il capitale circolante, potenziali acquisizioni che aumentano il valore e necessità aziendali generali.

Gli investitori hanno ottenuto solidi diritti di registrazione: Rezolve deve presentare una dichiarazione di registrazione per la rivendita entro 7 giorni dalla chiusura e ottenere l’efficacia entro 30 giorni (60 giorni se sottoposta a revisione completa). L’azienda è vincolata a non annunciare o emettere ulteriori azioni per 60 giorni dopo l’efficacia, con alcune limitate eccezioni. Gli accordi chiave — incluso il Contratto di Acquisto, l’Accordo con l’Agente di Collocamento e l’Accordo sui Diritti di Registrazione — sono depositati come Allegati 10.1-10.3.

Rezolve AI plc (RZLV) completó el 25 de julio de 2025 una inversión privada en acciones públicas (PIPE) por 50 millones de dólares, emitiendo 20 millones de acciones ordinarias a 2,50 dólares cada una bajo las exenciones Reg D y §4(a)(2).

A.G.P./Alliance Global Partners actuó como agente colocador, con derecho a una comisión en efectivo del 7,0 % (parcialmente compensada por un crédito del 3,5 % vinculado a compradores específicos) y hasta 130.000 dólares en gastos reembolsables. Los ingresos netos financiarán capital de trabajo, posibles fusiones y adquisiciones que aporten valor y necesidades corporativas generales.

Los inversores recibieron sólidos derechos de registro: Rezolve debe presentar una declaración de registro para reventa dentro de los 7 días posteriores al cierre y lograr la efectividad dentro de 30 días (60 días si se revisa completamente). La compañía tiene prohibido anunciar o emitir acciones adicionales durante 60 días después de la efectividad, con algunas excepciones limitadas. Los acuerdos clave —incluyendo el Acuerdo de Compra, el Acuerdo con el Agente Colocador y el Acuerdo de Derechos de Registro— están archivados como Anexos 10.1-10.3.

Rezolve AI plc (RZLV)는 2025년 7월 25일 5,000만 달러 규모의 사모 공개 주식 투자(PIPE)를 완료했으며, Reg D 및 §4(a)(2) 면제를 적용하여 주당 2.50달러에 2,000만 보통주를 발행했습니다.

A.G.P./Alliance Global Partners가 배치 에이전트로 활동했으며, 특정 구매자와 연계된 3.5% 크레딧 일부 상쇄를 포함해 7.0% 현금 수수료와 최대 13만 달러의 환급 가능한 비용을 받습니다. 순수익은 운전자본, 잠재적인 가치 증대 인수합병 및 일반 기업 필요에 사용될 예정입니다.

투자자들은 강력한 등록 권리를 받았습니다: Rezolve는 마감 후 7일 이내에 재판매 등록 신청서를 제출해야 하며, 30일 이내(완전 검토 시 60일 이내)에 효력을 얻어야 합니다. 회사는 효력 발생 후 60일 동안 제한된 예외를 제외하고 추가 주식 발행이나 공시를 할 수 없습니다. 주요 계약서—구매 계약서, 배치 에이전트 계약서 및 등록 권리 계약서—는 부속서 10.1-10.3으로 제출되었습니다.

Rezolve AI plc (RZLV) a finalisé le 25 juillet 2025 un investissement privé en actions cotées (PIPE) de 50 millions de dollars, émettant 20 millions d’actions ordinaires à 2,50 dollars chacune, bénéficiant des exemptions Reg D et §4(a)(2).

A.G.P./Alliance Global Partners a agi en tant qu’agent de placement, percevant une commission en espèces de 7,0 % (partiellement compensée par un crédit de 3,5 % lié à des acheteurs spécifiques) ainsi que jusqu’à 130 000 dollars de frais remboursables. Les produits nets financeront le fonds de roulement, d’éventuelles acquisitions créatrices de valeur et les besoins généraux de l’entreprise.

Les investisseurs ont obtenu des droits d’enregistrement solides : Rezolve doit déposer une déclaration d’enregistrement pour la revente dans les 7 jours suivant la clôture et obtenir son efficacité dans les 30 jours (60 jours en cas d’examen complet). La société est interdite d’annoncer ou d’émettre des actions supplémentaires pendant 60 jours après l’efficacité, avec quelques exceptions limitées. Les accords clés — y compris le contrat d’achat, le contrat d’agent de placement et le contrat de droits d’enregistrement — sont déposés en annexes 10.1 à 10.3.

Rezolve AI plc (RZLV) hat am 25. Juli 2025 eine private Investition in börsennotierte Aktien (PIPE) in Höhe von 50 Millionen US-Dollar abgeschlossen und dabei 20 Millionen Stammaktien zu je 2,50 US-Dollar unter den Ausnahmen gemäß Reg D und §4(a)(2) ausgegeben.

A.G.P./Alliance Global Partners fungierte als Platzierungsagent und erhielt eine Barprovision von 7,0 % (teilweise durch einen 3,5 % Kredit für bestimmte Käufer ausgeglichen) sowie bis zu 130.000 US-Dollar erstattungsfähige Auslagen. Die Nettoerlöse dienen der Finanzierung des Betriebskapitals, potenzieller wertsteigernder Fusionen und Übernahmen sowie allgemeinen Unternehmensbedarfen.

Die Investoren erhielten umfassende Registrierungsrechte: Rezolve muss innerhalb von 7 Tagen nach Abschluss eine Registrierungsanmeldung für den Weiterverkauf einreichen und innerhalb von 30 Tagen (60 Tage bei vollständiger Prüfung) die Wirksamkeit erreichen. Das Unternehmen darf für 60 Tage nach Wirksamkeit keine weiteren Aktien ankündigen oder ausgeben, mit begrenzten Ausnahmen. Die wichtigsten Vereinbarungen – einschließlich des Kaufvertrags, des Platzierungsagentenvertrags und des Registrierungsrechtsvertrags – sind als Anlagen 10.1-10.3 eingereicht.

false 0001712762 0001712762 2025-07-25 2025-07-25 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-07-25 2025-07-25 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2025-07-25 2025-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

July 25, 2025

Date of Report (Date of earliest event reported)

 

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

3300 Nacogdoches Road

Suite 216

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

At the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) of bioAffinity Technologies, Inc. (the “Company”) held on July 25, 2025, the Company’s stockholders voted on six proposals, each of which is listed below and described in more detail in the Company’s Definitive Proxy Statement, which was filed with the Securities and Exchange Commission on June 2, 2025. With respect to each proposal, holders of the Company’s common stock, par value $0.007 per share (the “Common Stock”), were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of May 29, 2025 (the “Record Date”). On the Record Date there were 28,459,541 shares of the Company’s Common Stock issued and outstanding and entitled to vote at the 2025 Annual Meeting.

 

The following are the final results of voting on each of the proposals presented at the 2025 Annual Meeting:

 

Proposal No. 1: Election of Directors.

 

The stockholders elected each of the seven director nominees to serve on the Board until the 2026 Annual Meeting of Stockholders and until such director’s successor has been duly elected and qualified.

 

Nominee   Votes For   Votes Against   Abstentions   Broker Non-Votes
Maria Zannes   7,693,327   114,549   290,195   6,378,795
Steven Girgenti   7,658,376   111,500   328,195   6,378,795
Robert Anderson   7,632,198   109,288   356,585   6,378,795
Peter Knight   7,630,149   111,266   356,656   6,378,795
Gary Rubin   7,426,487   313,718   357,866   6,378,795
Roby Joyce, MD   7,629,826   112,674   355,571   6,378,795
Jamie Platt, PhD   7,631,076   111,611   355,384   6,378,795

 

Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

 

The stockholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
12,748,238   451,298   1,277,330   -

 

Proposal No. 3: Reverse Stock Split Proposal

 

The stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to effect a Reverse Stock Split.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
11,606,440   2,750,237   120,189   -

 

 

 

 

Proposal No. 4: Issuance of Shares of Common Stock Upon Exercise of Warrants

 

The stockholders approved the issuance of up to an aggregate of 2,926,166 shares of the Company’s Common Stock upon the exercise of common stock purchase warrants issued to institutional investors and designees of the placement agent in connection with the Company’s private placement offering that closed on February 26, 2025, that may be equal to or exceed 20% of the Company’s Common Stock outstanding before such offering.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
7,110,141   970,281   17,649   6,378,795

 

Proposal No. 5: Share Increase Amendment to the Certificate of Incorporation

 

The stockholders approved the Share Increase Amendment to the Company’s Certificate of Incorporation..

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
11,830,169   2,607,455   39,242   -

 

Proposal No. 6: Anti-Dilution Adjustment Proposal

 

The stockholders approved the anti-dilution provision of the Common Stock purchase warrants issued in connection with our public offering that closed on May 7, 2025 and the reduction in exercise price of the May 2025 Warrants (subject to a floor price of $0.10 per share) and corresponding increase in the number of shares issuable upon exercise thereof of up to an aggregate maximum of 49,907,811 shares of our Common Stock, resulting from the triggering of such anti-dilution provision.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
6,098,633   915,454   1,083,984   6,378,795

 

Proposal No. 7: Adjournment of the Annual Meeting

 

The stockholders approved the adjournment of the 2025 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal No. 3, Proposal No. 4, Proposal No. 5 and/or Proposal No. 6. However, such an adjournment was not necessary in light of the approval of Proposal Nos. 3, 4, 5 and 6 at the 2025 Annual Meeting.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
12,133,858   2,302,571   40,437   -

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  bioAffinity Technologies, Inc.
   
Dated: July 25, 2025 By: /s/ Maria Zannes
    Maria Zannes
    President and Chief Executive Officer

 

 

 

FAQ

How many shares did Rezolve AI (RZLV) issue in the July 2025 PIPE?

The company sold 20 million ordinary shares.

What price did investors pay for each Rezolve AI share in the PIPE?

The offering price was $2.50 per ordinary share.

How much gross capital did Rezolve AI raise from the PIPE financing?

Rezolve AI raised $50 million in gross proceeds.

What will Rezolve AI use the PIPE proceeds for?

Proceeds are earmarked for working capital, potential accretive M&A and general corporate purposes.

When must Rezolve AI file the resale registration statement for the new shares?

The company must file within 7 days of the PIPE’s closing.

What is the duration of Rezolve AI's lock-up on issuing additional shares?

Rezolve cannot issue or announce new equity for 60 days after the registration statement becomes effective.
bioAffinity Tech

NASDAQ:BIAFW

BIAFW Rankings

BIAFW Latest News

BIAFW Latest SEC Filings

BIAFW Stock Data

1.60M
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
SAN ANTONIO